Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.
The safety and efficacy of simultaneous administration of measles-mumps-rubella (MMR), diphtheria-tetanus-pertussis (DTP), and trivalent oral poliovirus (OPV) vaccines in a test group of 405 children were compared with the safety and efficacy of sequential administration of the same vaccines in a control group of 410 children given MMR followed by booster doses of DTP and OPV 2 months later. The study was double blind and placebo controlled with respect to DTP and OPV. Seroconversion rates to measles, mumps, and rubella exceeded 96% in both groups. Geometric mean titers to measles (P = .05) and rubella (P = .004) were higher in the test group, and titers of antibodies to the other seven antigens were similar in both groups. Clinical reaction data were analyzed in 248 of 405 test children and 249 of 410 control children. The rates of serious vaccine-associated reactions were low and similar in the two groups. Some minor side effects were reported more frequently in the test group, but these differences were judged to be related to study design rather than to differences in the safety of the two vaccine schedules. The results indicate that the safety and serologic efficacy of administering MMR simultaneously with reinforcing doses of DTP and OPV in the second year of life is equivalent to the safety and efficacy observed after administering these antigens separately.
Deforest
A
A
Department of Pediatrics, Temple University School of Medicine, Philadelphia, PA.
Long
S S
SS
Lischner
H W
HW
Girone
J A
JA
Clark
J L
JL
Srinivasan
R
R
Maguire
T G
TG
Diamond
S A
SA
Schiller
R P
RP
Rothstein
E P
EP
D000906:Antibodies / Q000032:analysis; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004311:Double-Blind Method; D004338:Drug Combinations / Q000008:administration & dosage; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D008458:Measles Vaccine / Q000008:administration & dosage; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000008:administration & dosage; D010567:Pertussis Vaccine / Q000008:administration & dosage; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage; D011897:Random Allocation; D012411:Rubella Vaccine / Q000008:administration & dosage; D013745:Tetanus Toxoid / Q000008:administration & dosage; D014612:Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017778:Vaccines, Combined
D000906:Antibodies; C051021:DTPP vaccine; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D010567:Pertussis Vaccine; D011054:Poliovirus Vaccine, Inactivated; D012411:Rubella Vaccine; D013745:Tetanus Toxoid; D014612:Vaccines; D017778:Vaccines, Combined